Periorificial Dermatitis

Azelaic Acid Therapeutic Cheat Sheet
azelaic acidAzelaic acid is a topical therapeutic agent which is FDA approved to treat papules and pustules of mild to moderate rosacea and mild to moderate acne vulgaris.  It was first approved by the FDA in 1995 and since its approval, has been used for many off-label conditions including disorders of hyperpigmentation. Its utility in various conditions can be attributed to its anti-microbial, anti-inflamm …
azelaic acid
Rosacea in Patients with Skin of Color: Not Common, But Certainly Not Rare
rosaceaRosacea is defined by facial erythema and telangiectasias, two features that are more difficult to appreciate in patients with skin of color. To refine our ability to diagnose rosacea in all skin types, on day two of the 2021 Skin of Color Update virtual conference, we had an informative, evidence-based lecture, “Recognizing, Diagnosing, and Treating Rosacea in Patients with Skin of Color,” by …
rosacea
Treatment of Periorificial Dermatitis With Novel Narrow Spectrum Sarecycline
Periorificial DermatitisBroad spectrum tetracyclines are a well-known, widely used, and often successful treatment for use in inflammatory skin pathologies such as acne and rosacea. However, the steady rise of antibiotic resistance and gut dysbiosis associated with broad spectrum tetracyclines emphasizes the importance and responsibility of antibiotic stewardship. Narrow spectrum antibiotics have become increasingly impo …
Periorificial Dermatitis
JDD January 2021 Issue Highlights: From COVID-19 Vaccine to Facial Rejuvenation
COVID-19 vaccineThe January issue of the Journal of Drugs in Dermatology focuses on Aesthetics Treatments, featuring an outstanding line-up of original articles from COVID-19 vaccine to facial rejuvenation. Straight from the JDD Editor’s desk, we share this month’s issue highlights: Aesthetic Office Disaster Preparedness and Response Plan is a proactive approach for aesthetic treatment offices to manage a …
COVID-19 vaccine